

**KENTUCKY BOARD OF PHARMACY
CASE REVIEW MEETING AGENDA
02/10/2026**

9:00 a.m. - 4:00 p.m.

Via VIDEO CONFERENCE

[https://us02web.zoom.us/meeting/register/gl5Yo6BCRcGRKhHD2zciHw](https://us02web.zoom.us/join/915906800000)

I. CASE REVIEW MINUTES: December 2nd, 2025

II. CASE UPDATES SINCE: November 17th, 2025

Executed Agreed Order

22-0207 M. Miller

23-0554 Highland Pharmacy

24-0076 KVK Tech

24-0107 A Gap Drug

24-0107 B R. Loudermelt

25-0028 B. Cherry

25-0089 B J. Hong

25-0095 A Advance Care Pharmacy

25-0095 C K. Phelps

25-0096 A Central Admixture Pharmacy Services INC.

25-0131 A B. Peeples

25-0187 A S. Blacketer

25-0205 D. Westrick

25-0209 C P. Cassaday

25-0225 B T. Vanway

Letters of Reprimand (Non-Discipline) issued pursuant to a completed Interim Agreed Order:

24-0081 C M. Beck

24-0120 S. Akers

24-0154 C M. Groene

24-0156 C J. Major

24-0157 C O. Ilesanmi

24-0158 C B. Willet

24-0505 H. Bainer

24-0506 J. Compton

24-0508 C. Mitchell

24-0510 J. Russell

24-0512 S. Bane

24-0519 R. Rhoades

24-0527 V. Emmanuel

24-0528 E. Thakore

24-0529 A. Khan

24-0530 B. Riddle

24-0600 S. King
24-0619 N. Kunze
24-0636 J. Short
24-0643 P. Webber
24-0646 J. Norton
24-0647 S. Skidmore
24-0657 D. Huelsman
24-0665 J. Wire
24-0669 J. Kostellic
24-0676 J. Varghese
24-0679 J. Capistrano
24-0681 J. Buttelwerth
24-0687 M. Kellihan
24-0690 M. Seddon
24-0692 S. Fritz
24-0706 C. Gamble
24-0707 B. Muhlstein
25-0008 B K. Klebeck

III. CASE EXTENSION REQUESTS:

- 25-0098 A PT00353227
- 25-0204 A P07114 B 018623
- 25-0215 A 015076
- 25-0221 A P00579 B 017980
- 25-0237 A PT00171792
- 25-0246 A P07348 B 014442 C 017150 D 024698
- 25-0258 A P06781 B 013856
- 25-0260 A P06838 B 008679
- 25-0262 A P01770 B 024206 C PT00379094
- 25-0263 A P06640 B 013546 C 014168

IV. CASES FOR REVIEW:

- 24-0114 A FL2914 A FL2914 B 024487 B 024487
- 24-0148 A 014175
- 25-0207 A P06451 B 015841
- 25-0220 A NJ1723 B 021593
- 25-0223 A P06904 B 010439 C 015052
- 25-0229 A P06932 B 011034
- 25-0230 A P06118 B 019318 C 010458 D PT00018644
- 25-0231 A P06573 B 012162
- 25-0234 A P07768 B 017078 C PT00025061
- 25-0235 A P07047 B 020461
- 25-0236 A P08134 B 012712
- 25-0239 A PT00383955
- 25-0240 A PT00376120
- 25-0241 A PT00387208
- 25-0245 A P06005 B 023858
- 25-0247 A P06315 B 016174 C 016824

- 25-0248 **A** P07219 **B** 016736
- 25-0249 **A** P02583 **B** 011633 **C** PT00390475
- 25-0250 **A** W00050
- 25-0251 **A** P07907 **B** 018880 **C** 025313
- 25-0252 **A** P06038 **B** 021651 **C** PT00368396
- 25-0254 **A** PA1214 **B** 023334
- 25-0256 **A** P07736 **B** 022952
- 25-0257 **A** P08401 **B** 017594
- 25-0259 **A** P06023 **B** 018873
- 25-0261 **A** P07418 **B** 015259 **C** PT00014934
- 25-0264 **A** P06144 **B** 018103 **C** 019369
- 25-0266 **A** PT00348806

V. ADJOURN

ATTENTION: A portion of the meeting may be held in closed/executive session for the purpose of discussing and deliberating upon open investigations, which are preliminary matters that may result in litigation being filed on behalf of the Board and include the review of information required to be conducted in privacy according to federal and state law (under Agenda Items III and IV). The specific statutory sections providing exemptions are KRS 61.810(1)(c) KRS 61.878(1)(a) KRS 61.810(1)(j) KRS 61.878(1)(h) KRS 61.810(1)(k).

Following discussion and deliberation, any and all action will be taken in open/public session.

